Day 2 recordPCAC unfavorable

Peptide dossier / July 23–24, 2026

Emideltide (DSIP)

Emideltide had older human studies, but the record was small, methodologically uneven and largely intravenous rather than the nominated subcutaneous route.

Read the verdict Hear the testimony

free base6–7–1Yes · No · Abstain · n=14Recorded at 03:15:17.600 acetate6–7–1Yes · No · Abstain · n=14Recorded at 03:22:37.359

Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.

Editorial review

The central tension in this record.

FDA staff and PCAC both opposed inclusion of both forms.

Evidence signal01

There is a historical human-study record

Emideltide was not evaluated from a blank slate. FDA reviewed older human sleep, narcolepsy and withdrawal literature.

FDA briefing pp. 23–40

Decisive limitation02

The evidence did not transfer cleanly to modern SC compounding

The exact chemical form was often unclear, the studies were small and methodologically limited, and the nominated subcutaneous route lacked direct effectiveness evidence.

FDA briefing pp. 30–40, 52–55

PeptideBase read

The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.

The case made in the room

Named speakers. Their strongest argument. Then the record check.

These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.

2named speaker moments

100%recording checked

Only named, source-reconciled speaker moments that were checked against the recording appear here. Statements remain attributed arguments unless the underlying evidence was independently established; no machine-caption wording is published as a quotation.

01Supports listing

Alex Tatem, MD

Board-certified urologist; fellowship-trained in male fertility, microsurgery and sexual medicine

Verify credentials

Attributed testimony

The historical-clinical case

Tatem cited older sleep and opioid-withdrawal literature in support of emideltide. The studies he described were small and historical; the testimony did not turn them into modern evidence for the exact nominated compounded form, route and uses.

emideltide session · attributed argument, not an established factAudio-checked paraphrasePlay the source01:36:15–01:37:35

02Opposes listing

Peter Lurie, MD, MPH

President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner

Verify credentials

Attributed testimony

The hearing-wide case against all seven

Lurie said CSPI opposed adding all seven substances. He argued that the FDA criteria had not been met, that compounded products could create consumer risks, and that listing could weaken incentives for development through the standard drug-approval pathway.

Opening public hearing · explicitly applied to all seven substancesAudio-checked paraphrasePlay the source00:57:09–00:57:55

Claim-specific check

Historical sleep and withdrawal studies provide a clinical signal for emideltide.

Historical small studies

What supports it

The hearing cited older, small studies. Their identity, methods, exact material and relationship to the nominated subcutaneous use were not fully resolved in the reviewed record.

FDA’s answer

FDA found no adequate study supporting effectiveness for the nominated uses and no safety data for the proposed subcutaneous route.

FDA Day 2 presentation · 02:19:28

PeptideBase assessment

Older studies are a lead worth locating and reappraising. They are not enough to establish modern effectiveness or subcutaneous safety.

Why the judgments diverged

This was the one subject on which the two judgments aligned.

Historical studies and access arguments did not overcome the record’s unresolved effectiveness, route and safety problems. The committee majority recommended against both forms, consistent with FDA staff’s position.

Record synthesis; no divergence occurred for this subject

Claim versus record

What the official material supports—and what it does not.

These are recurring propositions in the wider peptide discussion, not attributed speaker quotations.

Route transfer

Recurring claim

Older intravenous sleep studies establish the nominated subcutaneous use.

Official record

FDA found no effectiveness study using the nominated SC route for chronic insomnia; the available clinical data it located used intravenous administration.

What it does not establish

Evidence from one route cannot be assumed to establish exposure, effectiveness or safety for another route.

FDA briefing pp. 23–31

Breadth of evidence

Recurring claim

The historical clinical record is robust across insomnia, narcolepsy and withdrawal.

Official record

FDA described small and methodologically limited studies; the narcolepsy evidence included a single-subject case report, and withdrawal studies lacked key controls or randomization.

What it does not establish

Historical use can be relevant, but weak design, small samples, subjective endpoints and uncertain chemical form restrict what the studies establish.

FDA briefing pp. 30–40, 52–55

Evidence architecture

Eight questions applied consistently.

“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.

Evidence questions applied to Emideltide (DSIP), with FDA’s record summary and a locator.
Evidence question	Status	FDA-record summary	Locator
Human clinical evidence	limited	Older small IV studies and a single-subject narcolepsy report were identified.	Briefing pp. 23–40
Nonclinical evidence	indirect	Preclinical sleep-related material existed but did not resolve the nominated human uses.	Briefing pp. 40–48
Exact-form match	contested	Nominations and clinical references often did not clearly identify free base versus acetate.	Briefing pp. 8–19, 22–23
Nominated-route match	absent	FDA identified no effectiveness study using the nominated SC route.	Briefing p. 30
Evaluated-use match	limited	The record touched all three uses, but methods, samples and consistency were inadequate.	Briefing pp. 23–40
Product characterization	limited	FDA considered both forms not well characterized and identified impurity, aggregation and endotoxin gaps.	Briefing pp. 8–19
Human safety	limited	Small IV studies reported some adverse effects, including hypotension in withdrawal studies; SC safety was not established.	Briefing pp. 48–55
Historical compounding use	limited	FDA found published and market information too limited to characterize historical compounding use.	Briefing pp. 20–22

Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation

FDA findings

Five parts of the staff case.

01characterizationBoth emideltide free base and emideltide acetate were considered not well characterized.Day 2 pp. 38, 41
02:10:24 02effectivenessFDA found no adequate study supporting effectiveness for the nominated uses.Day 2 pp. 48–54
02:19:28 03safetyFDA found no safety data for the proposed subcutaneous route and insufficient information for the nominated uses.Day 2 pp. 55–62
02:30:08 04historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 63–67
02:32:42 05recommendationFDA proposed that neither emideltide free base nor emideltide acetate be included on the 503A Bulks List.Day 2 pp. 67–68
02:34:07

What changes the assessment

Open evidence gaps and direct sources.

A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.

Modern controlled trials using the exact form, SC route and nominated uses

Validated impurity, aggregate, endotoxin and finished-product specifications

Dose-related cardiovascular and hypotension safety evidence